At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 138 enrolled
Drug / intervention
Perampaneldrug
Likely dose
Perampanel 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 (Perampanel) as an Adjunctive Therapy in Patients With Refractory Partial Seizures
In Brief
A Phase 2 clinical trial evaluating Perampanel for Epilepsy. Completed, enrolled 138 participants across 47 sites in 14 countries.
Detailed Summary
The purpose of this study is to determine the safety of perampanel given as adjunctive, long-term treatment in patients with refractory partial onset seizures.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesAustralia, Belgium, Czechia, Estonia, Finland, France, Germany, Latvia, Lithuania, Netherlands, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2006
Enrollment StartOct 2006
Primary CompletionJun 2014
Study CompletionJul 2014
TodayJul 2026
First PostedAug 24, 2006
Enrollment StartOct 1, 2006
Primary CompletionJun 1, 2014
Study CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 7.7 yearsPosted 19.9 years ago
Interventions
Perampaneldrug
Perampanel 2 mg to 12 mg, once daily during the OLE study